Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of M281 in generalized myasthenia gravis
2018-003618-41Phase 2Suspended
- Sponsor
- Momenta Pharmaceuticals
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Momenta Pharmaceuticals. Primary endpoint: Safety and tolerability of M281. Started Mar 2019; status: suspended.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2018-003618-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003618-41.